TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19298319

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Alcohol education
Number of subjects: 67
Study: 17056383

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 2% gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subconjunctival lidocaine 2% injection
Number of subjects: 100
Study: 14499424

Group type: EXPERIMENTAL
Intervention: Active laser exposure (Gallium‐Aluminum‐Arsenide laser)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo laser exposure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients with chronic orofacial pain
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison between active laser and placebo
Number of subjects: 24
Study: 10867305

Group type: EXPERIMENTAL
Intervention: Immediate, rent-free, abstinent-contingent housing during a 2-month Behavioral Day Treatment program
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Behavioral Day Treatment attendance
Number of subjects: 141

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 141
Study: 1703237

Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at doses less than or equal to 3.9 g/m2 administered intravenously over 1 hour
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at doses greater than or equal to 5.28 g/m2 administered over 6 hours
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at 10 g/m2
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at 8 g/m2 recommended for phase II
Number of subjects: 38
Study: 6867755

Group type: EXPERIMENTAL
Intervention: Sequential MTX/5‐FU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential 5‐FU/MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous MTX/5‐FU
Number of subjects: 0
Study: 30273717

Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group (no ACP video)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Basic care preference
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Intensive care preference
Number of subjects: 328
Study: 29961606

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study: 26813483

Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral therapy (CBT) delivered via email, 10 to 12 sessions conducted by a psychiatrist and a psychiatry resident.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 93
Study: 24352960

Group type: EXPERIMENTAL
Intervention: DDGS at 0.5% of BW daily (DM basis)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: DDGS at 1% of BW daily (DM basis)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 70
Study: 21978965

Group type: EXPERIMENTAL
Intervention: Celivarone 300 mg once daily for 6 months
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Celivarone 300 mg once daily for 6 months (subgroup analysis)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Celivarone (both dosages)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 20451927

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25-0.75 mg/day
Number of subjects: 141
Study: 18046434

Group type: EXPERIMENTAL
Intervention: Perindopril (ACE-inhibitor)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 15944885

Group type: EXPERIMENTAL
Intervention: Raising arm to overhead height task (hard task)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Functional tasks
Number of subjects: 25
Study: 12444517

Group type: EXPERIMENTAL
Intervention: Functional treatment (15 days strapping plus early controlled mobilization)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cast immobilization (21 days plaster cast)
Number of subjects: 121
Study: 10349576

Group type: EXPERIMENTAL
Intervention: School-based intervention program addressing sun protection, behavioral strategies, and structural changes over three years.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 3
Study: 7862474

Group type: EXPERIMENTAL
Intervention: Nurse home visitation from pregnancy through the second year of the child's life
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (comparison children)
Number of subjects: 400
Study: 2344111

Group type: EXPERIMENTAL
Intervention: Intensive outpatient treatment program
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intensive outpatient treatment program (after crossover)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Previous outpatient care
Number of subjects: 104
Study: 6424491

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol (2 mg four times daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional powder (20 mg four times daily by Spinhaler)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol
Number of subjects: 48
Study: 28872672

Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching (EMT) language intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Business as usual treatment
Number of subjects: 97
Study: 29950252

Group type: EXPERIMENTAL
Intervention: Oral methotrexate 10 mg once weekly for eight weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral corticosteroids 40 mg daily for eight weeks, then tapered
Number of subjects: 100
Study: 26888112

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Strength and endurance combined
Number of subjects: 173

Group type: COMPARATOR
Intervention: Physical activity recommendations only
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 173
Study: 24467875

Group type: EXPERIMENTAL
Intervention: Home-based group-mediated cognitive behavioral walking intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 194
Study: 24092823

Group type: EXPERIMENTAL
Intervention: Preoperative octreotide treatment (n=28)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Octreotide treatment for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Direct surgery (n=13)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Octreotide pretreatment (n=13)
Number of subjects: 65
Study: 21037456

Group type: EXPERIMENTAL
Intervention: Coconut fragrance
Number of subjects: 32

Group type: COMPARATOR
Intervention: Air
Number of subjects: 32
Study: 17882161

Group type: EXPERIMENTAL
Intervention: Laropiprant (single doses up to 900 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Laropiprant (multiple doses up to 450 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Laropiprant (single doses of 6 mg and higher)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Laropiprant (multiple doses up to 200 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Laropiprant
Number of subjects: 3
Study: 16896684

Group type: EXPERIMENTAL
Intervention: DCT (PASCAL dynamic contour tonometer)
Number of subjects: 92

Group type: COMPARATOR
Intervention: GAT (Goldmann applanation tonometry)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DCT
Number of subjects: 92

Group type: COMPARATOR
Intervention: GAT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DCT and GAT
Number of subjects: 92
Study: 12954255

Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release with epineurotomy
Number of subjects: 273

Group type: COMPARATOR
Intervention: Open carpal tunnel release without epineurotomy
Number of subjects: 273
Study: 10440427

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg tablet)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Theophylline (300 mg capsule)
Number of subjects: 15
Study: 8680375

Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin (8 mg.mL‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Inhaled [desArg9]-bradykinin (8 mg.mL‐1)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 4
Study: 1775780

Group type: EXPERIMENTAL
Intervention: Roles of oncology nurses in clinical trials (direct care provider, educator, advocate, data collector, primary investigator, member of the IRB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse's role in informing subjects and facilitating decision making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse's role in protocol adherence and monitoring
Number of subjects: 0
Study: 6811448

Group type: EXPERIMENTAL
Intervention: prednisolone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: chloroquin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: clofazimine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 30865075

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General health education (Control)
Number of subjects: 0
Study: 28882549

Group type: COMPARATOR
Intervention: Standard contraceptive counseling
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Counseling with information about IUD self-removal
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Both groups (with and without self-removal information)
Number of subjects: 361
Study: 26842107

Group type: EXPERIMENTAL
Intervention: Mirtazapine (starting at 15 mg daily for 2 weeks, increasing to 30 mg daily thereafter, for up to 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24290781

Group type: EXPERIMENTAL
Intervention: Body-optimized group
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: HR + Body-optimized group
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: HR-optimized group
Number of subjects: 423
Study: 22931392

Group type: EXPERIMENTAL
Intervention: High importance (OR 2.94; 1.15, 7.50)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: High confidence (OR 2.88; 1.46, 5.68)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: High confidence (OR 3.29; 1.12, 9.62)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Mean readiness to change drinking scores: 3.9 (SD 3.0)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Mean importance to change drinking scores: 2.7 (SD 2.2)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Mean confidence to change drinking scores: 7.2 (SD 3.0)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Mean readiness to change smoking scores: 4.6 (SD 2.6)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Mean importance to change smoking scores: 5.3 (SD 2.6)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Mean confidence to change smoking scores: 5.9 (SD 2.7)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: 108 (29%) reported no unhealthy alcohol use at follow-up.
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: 13% (33) reported no longer smoking at follow-up.
Number of subjects: 461
Study: 21290832

Group type: EXPERIMENTAL
Intervention: Combined laser group (n = 22)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Red light group (n = 19)
Number of subjects: 41
Study: 17129220

Group type: EXPERIMENTAL
Intervention: Propofol (sedation score of two)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midazolam (sedation score of two)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol (sedation score of three)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midazolam (sedation score of three)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electric dental pulp stimulation (invasive)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Picture recall test (non‐invasive)
Number of subjects: 10
Study: 15865615

Group type: EXPERIMENTAL
Intervention: Local electrostatic air cleaners
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-functioning electrostatic unit (Control)
Number of subjects: 80
Study: 11800220

Group type: EXPERIMENTAL
Intervention: Self-help group receiving additional multiple-contact telephone counseling
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard self-help group
Number of subjects: 200
Study: 9821992

Group type: EXPERIMENTAL
Intervention: Intravenous esmolol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intravenous diltiazem
Number of subjects: 64
Study: 7648069

Group type: EXPERIMENTAL
Intervention: Use of a hand-held osmolality probe for hydration monitoring
Number of subjects: 28
Study: 2473725

Group type: EXPERIMENTAL
Intervention: 0.25% AA‐673 eye drops
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 11
Study: 324340

Group type: EXPERIMENTAL
Intervention: Discharge at 48 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discharge at 6-7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discharge at 48 hours (hernia patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discharge at 6-7 days (hernia patients)
Number of subjects: 0
Study: 30736951

Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 0.2 mg/kg SC
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 1.0 mg/kg SC
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 0.2 mg/kg IR
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 1.0 mg/kg IR
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ivermectin (IVM) 0.2 mg/kg SC
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) (all groups)
Number of subjects: 125
Study: 28150304

Group type: EXPERIMENTAL
Intervention: Fluid restriction
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 151
Study: 25407026

Group type: COMPARATOR
Intervention: Hartmann's solution (HS)
Number of subjects: 60
Study: 23221674

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Number of subjects: 1

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1
Study: 21762232

Group type: EXPERIMENTAL
Intervention: Venner A.P. Advance (APA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: GlideScope Ranger (GSR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 30
Study: 20191820

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) therapy
Number of subjects: 70
Study: 16669847

Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg twice daily for 5 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem (100 mg twice daily for 5 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 12525736

Group type: EXPERIMENTAL
Intervention: Thalidomide (TL) at doses up to 200 mg/d
Number of subjects: 20
Study: 10978246

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonfat isocaloric meal
Number of subjects: 50
Study: 8826285

Group type: EXPERIMENTAL
Intervention: Feeder standing position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feeder sitting position
Number of subjects: 0
Study: 1425819

Group type: EXPERIMENTAL
Intervention: Combination therapy with bromocriptine and levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 0
Study: 3939673

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg bid)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 30412607

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 220

Group type: COMPARATOR
Intervention: Postconditioning
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Injured myocardium
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Low MCE injured myocardium
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Larger infarction
Number of subjects: 220
Study: 26757318

Group type: EXPERIMENTAL
Intervention: Massage intervention (one massage per night for two or three nights)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 78
Study: 24799539

Group type: EXPERIMENTAL
Intervention: Practice-Tailored Facilitation Intervention (Early practices)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Practice-Tailored Facilitation Intervention (Late practices)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline performance (Early practices)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline performance (Late practices)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall improvement after 6-month intervention
Number of subjects: 30
Study: 22652593

Group type: EXPERIMENTAL
Intervention: G-CSF 10 μg/kg per day intravenously for 5 consecutive days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (similar treatments without G-CSF)
Number of subjects: 24
Study: 20028939

Group type: EXPERIMENTAL
Intervention: 100 mg diazoxide at bedtime
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 18541589

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3 g CaCO3 daily, providing 1200 mg elemental Ca)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 930
Study: 15168290

Group type: EXPERIMENTAL
Intervention: V.A.C. (KCI, Austria)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Flammazine (Smith and Nephew, Germany)
Number of subjects: 1
Study: 11032056

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 258

Group type: COMPARATOR
Intervention: Dithranol cream
Number of subjects: 258
Study: 9315062

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Mastectomy (M)
Number of subjects: 184
Study: 8421798

Group type: EXPERIMENTAL
Intervention: DDAVP infusion (0.3 microliter per kilogram) during 15 to 30 minutes within one hour of anesthetic induction
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study: 2430084

Group type: EXPERIMENTAL
Intervention: 7S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Number of subjects: 20
Study: 29796857

Group type: EXPERIMENTAL
Intervention: Cross-education (strength training of the non-injured leg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 43
Study: 27015889

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: QoL tools (PGA, Kansas City Cardiomyopathy Questionnaire, EuroQoL‐5D)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: 6MWT
Number of subjects: 459
Study: 23800990

Group type: EXPERIMENTAL
Intervention: Health-related dysfunctional beliefs
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 410
Study: 22730940

Group type: EXPERIMENTAL
Intervention: Phone-based motivational interviewing program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study: 19852658

Group type: EXPERIMENTAL
Intervention: Conventional elastomeric ligatures
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Super Slick elastomeric ligatures
Number of subjects: 9
Study: 18417741

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 50 IU/kg three times per week
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000 IU once weekly
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 20,000 IU every 2 weeks for 36 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU every 4 weeks for 64 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: All regimens
Number of subjects: 38
Study: 16184544

Group type: EXPERIMENTAL
Intervention: Basiliximab 20 mg on days 0 and 4; tacrolimus delayed until renal function improved
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no basiliximab; tacrolimus on first postoperative day)
Number of subjects: 45
Study: 12538202

Group type: EXPERIMENTAL
Intervention: Minute sphere acupressure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 53
Study: 10749154

Group type: EXPERIMENTAL
Intervention: Frontalis muscle flap advancement technique
Number of subjects: 8
Study: 8650419

Group type: EXPERIMENTAL
Intervention: Ambulatory respiratory rehabilitation (2 hours per session, 3 times per week for 7 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ambulatory respiratory rehabilitation
Number of subjects: 88
Study: 1517943

Group type: EXPERIMENTAL
Intervention: Domperidone for 4 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Domperidone for 8 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 17
Study: 6611026

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach to substance abuse prevention (20 sessions) implemented by peer leaders
Number of subjects: 1311

Group type: COMPARATOR
Intervention: Cognitive-behavioral approach to substance abuse prevention (20 sessions)
Number of subjects: 1311
Study: 30668478

Group type: EXPERIMENTAL
Intervention: Unilateral training with non-dominant hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral training with both hands
Number of subjects: 0
Study: 29949584

Group type: EXPERIMENTAL
Intervention: High rebound mattress topper (HR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low rebound mattress topper (LR)
Number of subjects: 30
Study: 27348271

Group type: EXPERIMENTAL
Intervention: Opt-out palliative care consultation
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Opt-in palliative care consultation
Number of subjects: 12000
Study: 25190617

Group type: EXPERIMENTAL
Intervention: Tailored duration of ECS therapy following an initial therapeutic period of 6 months
Number of subjects: 864

Group type: COMPARATOR
Intervention: Standard duration of ECS therapy for 24 months
Number of subjects: 864